| |
| |
|
| Insider
Information: |
Higgins John L |
| Relationship: |
Director |
| City: |
Palo Alto |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
2,806,928 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$48,561,124 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
2,806,928 |
|
|
| Total
Value |
$48,561,124 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
11
|
|
Stock
price went up :
|
0
|
5
|
| Stock
price went down : |
0
|
6
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -38.4%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ligand Pharmaceuticals Inc |
LGND |
Director |
2022-12-28 |
417,695 |
2007-02-01 |
0 |
Premium* |
|
|
Techne Corp |
TECH |
Director |
2024-05-14 |
36,608 |
2013-10-31 |
0 |
Premium* |
|
|
OmniAb, Inc |
OABI |
Director |
2024-01-30 |
2,352,625 |
2022-11-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
165 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2018-01-24 |
4 |
AS |
$165.00 |
$3,712,500 |
D/D |
(22,500) |
111,700 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & CEO |
• • – |
2012-12-05 |
4 |
B |
$18.03 |
$36,060 |
D/D |
2,000 |
112,025 |
2.81 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & CEO |
• • – |
2013-08-19 |
4 |
OE |
$16.14 |
$105,814 |
D/D |
6,556 |
116,581 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & CEO |
• • – |
2013-10-22 |
4 |
OE |
$10.05 |
$169,763 |
D/D |
10,518 |
117,099 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2017-02-15 |
4 |
D |
$104.28 |
$448,821 |
D/D |
(4,304) |
118,360 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & CEO |
• • – |
2014-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
119,099 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2019-01-10 |
4 |
OE |
$16.14 |
$545,371 |
D/D |
33,790 |
119,209 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2016-03-07 |
4 |
S |
$102.44 |
$1,110,027 |
D/D |
(10,833) |
119,664 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2018-05-15 |
4 |
OE |
$16.14 |
$200,217 |
D/D |
12,405 |
119,824 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & CEO |
• • – |
2013-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
120,025 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & CEO |
• • – |
2013-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
120,025 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & CEO |
• • – |
2014-08-15 |
4 |
B |
$54.97 |
$54,970 |
D/D |
1,000 |
120,099 |
2.81 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2015-08-06 |
4 |
S |
$110.79 |
$516,946 |
D/D |
(4,666) |
121,378 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2016-09-22 |
4 |
S |
$117.34 |
$352,020 |
D/D |
(3,000) |
122,664 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2017-02-24 |
4 |
D |
$100.38 |
$480,118 |
D/D |
(4,783) |
122,745 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2016-03-08 |
4 |
OE |
$21.00 |
$126,000 |
D/D |
6,000 |
125,664 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2015-06-09 |
4 |
S |
$92.53 |
$928,809 |
D/D |
(10,000) |
126,044 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2019-01-23 |
4 |
D |
$111.78 |
$756,192 |
D/D |
(6,765) |
126,090 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & CEO |
• • – |
2014-02-12 |
4 |
OE |
$9.96 |
$168,075 |
D/D |
16,875 |
127,974 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2017-03-08 |
4 |
S |
$107.06 |
$428,240 |
D/D |
(4,000) |
128,969 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2019-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
13,646 |
129,258 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2016-02-15 |
4 |
D |
$85.97 |
$214,237 |
D/D |
(2,492) |
130,497 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2017-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
19,392 |
132,969 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2016-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
11,611 |
132,989 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2019-02-15 |
4 |
D |
$120.86 |
$594,269 |
D/D |
(4,917) |
133,982 |
0 |
- |
|
165 Records found
|
|
Page 3 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
